ABOUT BIOMARIN
Founded 25 years ago, BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery.
Learn More about BioMarin ⌃CAREERS AT BIOMARIN
Our focus on genetic disease gives us the opportunity to truly impact lives.
Learn More about careers with BioMarin ⌃
Patient & Community Support
Treatment is only the beginning.
We are committed to the communities we treat beyond the therapies
OUR PIPELINE
We maximize the impact of genetic innovation to develop transformative therapies.
Each drug candidate we pursue is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address.
View Now ⌃-
January 8, 2023BioMarin Announces Stable and Durable Annualized Bleed Control for ROCTAVIAN™ in Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Secondary Efficacy Endpoints at 3-Year Analysis
-
January 4, 2023BioMarin to Present at 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, at 10:30 am PT /1:30 pm ET, in San Francisco, CA
-
January 3, 2023European Medicines Agency Validates Application for Extension of Indication for VOXZOGO® (vosoritide) for injection to Treat Children with Achondroplasia Under the Age of 2
-
November 23, 2022BioMarin Announces Advancements in FDA Review of ROCTAVIAN™ (Valoctocogene Roxaparvovec) for Adults with Severe Hemophilia A
-
November 7, 2022BioMarin Announces Incremental Progress on Biologics License Application (BLA) Review for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia A Program
-
November 3, 2022BioMarin to Participate in Two Upcoming Investor Conferences
-
October 26, 2022BioMarin Announces Third Quarter 2022 Year-over-Year Total Revenue Growth of 24% (31% Excluding KUVAN®)
-
October 12, 2022FDA Accepts BioMarin’s Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia A